So we presented this data at the 2026 EHA meeting in the late abstract session and also published this in the Lancet and the dataset I think really looks convincing that pirtobrutinib when given with venetoclax and rituximab is superior to the venetoclax rituximab standard of care for relapsed/refractory CLL. There’s a significant progression-free survival advantage even in the early interim analysis, and particularly the benefit was observed for patients who had previously been treated with a BTK inhibitor, especially if they’d actually progressed on a prior covalent BTK inhibitor...
So we presented this data at the 2026 EHA meeting in the late abstract session and also published this in the Lancet and the dataset I think really looks convincing that pirtobrutinib when given with venetoclax and rituximab is superior to the venetoclax rituximab standard of care for relapsed/refractory CLL. There’s a significant progression-free survival advantage even in the early interim analysis, and particularly the benefit was observed for patients who had previously been treated with a BTK inhibitor, especially if they’d actually progressed on a prior covalent BTK inhibitor. Those were the patients who really benefited the most from this PVR combination. It’s also important to note that the pirtobrutinib did not add a lot of additional toxicity beyond venetoclax and rituximab alone, and so I think this is becoming now a potential new standard of care. It’s waiting still for registration. But already in the US, we have it listed in our NCCN guidelines and we can get access to it. And I think it’s a great combination for patients, particularly progressing after covalent BTK inhibitors or chemoimmunotherapy in the past. I think a challenge is that the study did not include patients progressing after frontline venetoclax-based therapy. So it’s a bit of an extrapolation to use it in that population, although I think it still would be active. So I think the VR arm of the CLL-322 trial is particularly interesting because it’s really the first time with a modern patient population that we’ve seen the outcomes of venetoclax rituximab. If you remember in the Murano study, this was a population primarily of post-chemoimmunotherapy patients. And so in contrast to the Murano study here, these patients, about 80% had prior covalent BTK inhibitors. And what we saw was a significantly shorter progression-free survival with VR in this study compared to what we’d seen previously in the Murano study. Now, it’s always difficult to compare across studies, but I think it does give us a sense that these patients with covalent BTK inhibitor progression can have quite aggressive disease and can be quite challenging to treat. And so that’s why, as I was saying before, I think that using PVR in that population post-covalent BTK inhibitor could be a particularly helpful strategy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.